<PubmedArticle>
<MedlineCitation Owner="NLM" Status="PubMed-not-MEDLINE">
<PMID Version="1">16457713</PMID>
<DateCompleted>
<Year>2009</Year>
<Month>12</Month>
<Day>23</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic">
<Journal>
<ISSN IssnType="Electronic">1477-7517</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>3</Volume>
<PubDate>
<Year>2006</Year>
<Month>Feb</Month>
<Day>02</Day>
</PubDate>
</JournalIssue>
<Title>Harm reduction journal</Title>
<ISOAbbreviation>Harm Reduct J</ISOAbbreviation>
</Journal>
<ArticleTitle>Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.</ArticleTitle>
<Pagination>
<MedlinePgn>5</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The growing trends in opioid abuse, assessment of the abuse liability of prescription opioid products, and growing efforts by the pharmaceutical industry to develop 'abuse-resistant' formulations highlight a need to understand the features that make one product more 'attractive' than another to potential abusers. We developed a scale to measure the 'attractiveness' of prescription opioids to potential abusers, and used the scale to measure the relative attractiveness of 14 opioid analgesic products.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">First, the concept of attractiveness was empirically defined with a group of prescription opioid abusers and experts in opioid abuse using a process called Concept Mapping. Abuse liability consisted of two components: factors intrinsic to the drug formulation (e.g., speed of onset, duration) and factors extrinsic to drug formulation (e.g., availability, availability of alternatives, cost). A 17-item Opioid Attractiveness Scale (OAS) was constructed, focusing on factors intrinsic to the drug product.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 144 individuals participated in tests of validity and reliability. Internal consistency was excellent (Cronbach's alpha = 0.85-0.94). Drug rankings based on OAS scores achieved good inter-rater agreement (Kendall's W 0.37, p &lt; 0.001). Agreement on drug OAS scores between the developmental sample and a confirmation sample was good (IntraClass Correlations [ICC] of 0.65-0.69). Global ratings of overall attractiveness of the 14 selected opioid products by substance abuse counselors corresponded with the rankings based on OAS ratings of the abuser group. Finally, substance abuse counselors completed the OAS, yielding a high level of correspondence with ratings by the abuser group (ICC = 0.83, p = 0.002). The OAS differentiated attractiveness among 14 selected pharmaceutical opioid products. OxyContin, Dilaudid, and Percocet were ranked highest (most attractive); Talwin NX and Duragesic were ranked lowest (least attractive).</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">An initial examination of the psychometric properties of the OAS suggests that it is a valid and reliable scale. The OAS may be useful in providing important guidance on product features that are attractive to potential abusers.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Butler</LastName>
<ForeName>Stephen F</ForeName>
<Initials>SF</Initials>
<AffiliationInfo>
<Affiliation>Pain and Opioid Division, Inflexxion Inc., Newton, MA, USA. sfbutler@inflexxion.com</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Benoit</LastName>
<ForeName>Christine</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Budman</LastName>
<ForeName>Simon H</ForeName>
<Initials>SH</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Fernandez</LastName>
<ForeName>Kathrine C</ForeName>
<Initials>KC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McCormick</LastName>
<ForeName>Cynthia</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Venuti</LastName>
<ForeName>Synne Wing</ForeName>
<Initials>SW</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Katz</LastName>
<ForeName>Nathaniel</ForeName>
<Initials>N</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2006</Year>
<Month>02</Month>
<Day>02</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>England</Country>
<MedlineTA>Harm Reduct J</MedlineTA>
<NlmUniqueID>101153624</NlmUniqueID>
<ISSNLinking>1477-7517</ISSNLinking>
</MedlineJournalInfo>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2005</Year>
<Month>01</Month>
<Day>05</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2006</Year>
<Month>02</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2006</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2006</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2006</Year>
<Month>2</Month>
<Day>7</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">16457713</ArticleId>
<ArticleId IdType="pii">1477-7517-3-5</ArticleId>
<ArticleId IdType="doi">10.1186/1477-7517-3-5</ArticleId>
<ArticleId IdType="pmc">PMC1382206</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Pain Med. 2003 Mar;4(1):21-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12873275</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Alcohol Depend. 2003 Apr 1;69(3):215-32</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12633908</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pain Symptom Manage. 2004 Aug;28(2):176-88</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15276196</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Curr Opin Investig Drugs. 2004 Jan;5(1):61-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">14983975</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anesthesiology. 2002 Oct;97(4):827-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12357147</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Pain Symptom Manage. 2002 Apr;23(4):292-300</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">11997198</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>MMWR Morb Mortal Wkly Rep. 2000 Jul 21;49(28):636-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10926306</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Compr Psychiatry. 1992 May-Jun;33(3):190-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1591911</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Psychiatry. 2005 Aug;162(8):1432-40</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16055764</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>MMWR Morb Mortal Wkly Rep. 2005 Sep 9;54(35):870-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16151371</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drug Alcohol Depend. 1990 Jun;25(3):315-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">2347295</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Addict. 1970 Dec;5(4):717-30</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">4400244</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>JAMA. 1972 Jan 10;219(2):171-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">5066605</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Res Publ Assoc Res Nerv Ment Dis. 1968;46:333-46</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">5723801</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Soc Sci Med B. 1981 Oct;15(4):521-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6172856</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Addict. 1982 Apr;17(3):473-91</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">7095925</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Biometrics. 1977 Mar;33(1):159-74</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">843571</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Drugs R D. 2005;6(2):91-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15777102</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CA Cancer J Clin. 1960 Jan-Feb;10:33-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">13849265</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</PubmedArticle>